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Atrial fibrillation (AF) is the most common form of sustained cardiac arrhythmia. AF 
requires a trigger that initiates the arrhythmia, and the presence of a predisposing substrate 
that perpetuates it. Approximately 90% of paroxysmal AF episodes are initiated by triggers 
within the pulmonary veins (PVs), and the elimination of these foci, together with 
modification of the substrate, is the basis of most radiofrequency ablation (RFA) techniques.  
The aim of these studies was to illuminate various aspects of atrial fibrillation mechanisms, 
mapping and ablation methods, and clinical results.  
Methods
The patients in these studies had either symptomatic paroxysmal, persistent or long-standing 
persistent AF, and had failed to respond to at least one anti-arrhythmic drug. Patients 
underwent electrophysiological study and RFA in a fasting, sedated state. Vascular access 
was obtained, and after transseptal puncture, an irrigated-tip ablation catheter was used for 
mapping and ablation of the left atrium (LA) and for additional lines or focal ablation. In the 
course of this study, the techniques employed to achieve PV isolation evolved, and details of 
the isolation techniques involved at each stage are described in each paper. 
In the first study, complex fractionated atrial electrograms (CFAE) during AF were mapped 
in both atria. In the second, we specifically monitored the atrio-PV conduction delay (the 
shortest interval from local atrial electrogram to the PV potential) in each PV before and 
during ablation. In the third study, patients underwent either a conventional ablation 
procedure or a magnetic guided procedure with or without an irrigated catheter. Two cardiac 
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biomarkers, troponin T (TnT) and cardiac creatine kinase (CKMB) were used to compare the 
myocardial injury created by the different catheters. In the next study, atrial volume 
calculations based on cardiac computed tomography were performed, and the cardiac 
biomarker N-terminal pro-brain natriuretic peptide (NT-pro-BNP) was measured, before 
ablation and at long-term follow-up. The final clinical follow-up study employed a quality-
of-life questionnaire.  
Results and conclusions 
CFAEs are preferentially distributed in specific areas in both atria. Persistent AF patients had 
more CFAEs than those with paroxysmal AF, and CFAEs were more widespread in both 
atria. Temporal signal stability also appeared to be higher in persistent AF. 
Atrio-PV conduction delay was more frequently observed in the left common PV and both of 
the superior PVs during PV isolation. Veins with focal activity displayed a higher incidence 
of conduction delay. 
The procedure and total ablation times were longer, and time-corrected release of TnT was 
higher, when the remote magnetic system was used in AF ablation. There was a statistically 
significant positive correlation between total ablation time and post-ablation levels of TnT 
and CKMB in all groups.  
LA volume and NT-pro-BNP levels fell only after successful AF ablation, and NT-pro-BNP 
correlated with LA volume both at baseline and follow-up. The arrhythmia burden also 
correlated with both NT-pro-BNP and LA volume. A decrease in NT-pro-BNP after RFA 
may be a marker of ablation success.  
AF may recur late, but most AF recurrences occurred within six months of the RFA 
procedure.  
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LA = Left Atrium 
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The first descriptions of one of the clinical signs of atrial fibrillation (AF), chaotic 
irregularity of the pulse, date back several hundred years. As early as in the seventeenth 
century Harley described “fibrillation of the auricles” in animals (1). In the early twentieth 
century Einthoven’s string galvanometer made it possible to record the electrical activity of 
the heart, and the clinical and physiological attributes of AF were described. Lewis was the 
first to conclude that AF was the atrial rhythm underlying the irregularity of the pulse (2). At 
first, he postulated that activity from one or more heterogeneous centres accounted for both 
premature beats, regular tachycardia and finally, AF (3). Later he produced the circus 
movement hypothesis (4), which in the course of time was developed in complexity, 
encompassing the possibility of a mother rotor giving rise to several independent rotors.  
Various theories of the mechanisms of atrial fibrillation evolved further, and in the late 
nineteen-fifties Moe proposed the “multiple wavelet hypothesis” (5). His work on 
experimental models led him to postulate that AF was self-sustaining and depended on 
fractionation of wave fronts around areas of refractory tissue. About thirty years ago, Allessie 
presented electrophysiological evidence for the importance of atrial conduction blocks for 
the perpetuation of AF (6). During further work his group demonstrated re-entry and rotor 
mechanisms (7), not far from what had been suggested more than fifty years previously by 
Lewis. Evidence shows that sustained AF requires continuously depolarizing wave fronts, 
favoured by the remodelling of the atria, with shortening of the refractory period and 
formation of areas of slow conduction. 
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Haissaguerre’s key article, which demonstrated the importance of the pulmonary veins (PVs) 
for the initiation of paroxysmal AF (8), started the era of ablation treatment of AF in the late 
1990s. However, the mechanisms of AF have not been fully elucidated. 
5.1.2 Epidemiology 
AF is the most common form of sustained cardiac arrhythmia, affecting approximately 1-2 
percent of the general population (9). In the western world this proportion seems likely to 
increase during the coming decades, mainly due to the aging of the populations. The 
prevalence of the arrhythmia increases with age, occurring in up to 5 percent of people aged 
75 or over. The number of AF patients may be underestimated due to unrecognized, 
asymptomatic AF, which may be missed in epidemiological studies (10).  
AF increases the risk of stroke (11) and is also recognized as an independent predictor of 
morbidity and mortality (12, 13), with a two-fold increase in death rate. Stroke and related 
complications are the main causes of the increased morbidity and mortality in AF patients, 
but impaired left ventricular function by tachycardiomyopathy, loss of atrial contractile 
function and increased left ventricular end-diastolic filling pressure also contribute to AF-
related morbidity (14). 
5.1.3 Associated conditions 
According to the guidelines (15), AF can be described as a first diagnosed episode and later 
as recurrent AF.  The arrhythmia is then further defined as paroxysmal, persistent, 
longstanding-persistent or permanent (accepted) AF. AF is associated with a vast number of 
cardiovascular conditions, and on the basis of pathophysiology, secondary AF is 
distinguished from lone AF. Hypertension, heart failure, valvular dysfunction, 
cardiomyopathy, cardiac ischaemia, thyroid disorder, diabetes mellitus, obesity and sleep 
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apnoea are among the recognised risk factors, and lone AF is very much a diagnosis of 
exclusion, reported in approximately 10% of the total AF population (16). 
5.2  Pathophysiology  
5.2.1 Left atrial size 
Increased LA size is a risk factor for the development of AF, but AF in itself may also cause 
dilatation of the LA through the atrial remodelling process. Enlargement of the LA is often 
asymmetrical and may occur in the medial-lateral, as well as the superior-inferior axes. The 
standard assessment of LA size is based on echocardiographic measurement of the 
anteroposterior dimension in the parasternal long-axis view. Although this measurement has 
been used extensively in clinical and research work, it is now recognised as an inaccurate 
representation of LA size (17, 18). The relationship between LA size and cardiovascular 
disease burden in general has been shown to be stronger for the volume than for the diameter 
of the LA (18, 19).  
5.2.2 PVs and triggers of AF 
AF requires a trigger that initiates the arrhythmia, and the presence of a predisposing 
substrate that perpetuates it. Haissaguerre et al. demonstrated that approximately 90% of 
paroxysmal AF episodes were initiated by triggers within the PVs (8) and this discovery was 
the basis of most ablation techniques now in use (20, 21). The myocardial sleeves around the 
PVs and their junctions with the LA were early mentioned as a possible site of pathological 
importance (22), and conduction tissue with pacemaker activity has been demonstrated 
within the myocardial sleeves (23). The muscular tissue around the PV-LA junctions also has 
a very complex structure and local re-entry circuits in this area may also act as an important 
substrate for AF. Complex electrograms around the PV ostia have been recorded in clinical 
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studies (24, 25), supporting the importance of this area also for the perpetuation of AF. 
Targeting the area outside the PV ostia may therefore be important in AF ablation (26, 27).  
Previous studies have reported significant degree of variability in the anatomy of the PVs 
(28-30). Four distinct PV ostia are present in up to 60% of patients, but a common left trunk 
or an additional (middle) right-sided vein are frequent anatomical variants. Although the PVs 
account for the majority of triggers, other areas such as the superior caval vein, the vein of 
Marshall, the coronary sinus, the posterior LA and the LA auricle have also been shown to be 
important for AF initiation (8, 31-33).  
5.2.3 Substrate and modulating factors 
For AF to become sustained, the presence of an atrial substrate of sufficient mass is 
necessary for the maintenance of re-entrant circuits. Under the influence of both sympathetic 
and parasympathetic stimulation, the conduction properties of the atrial myocytes may 
change. This results in a shortening of the duration of atrial refractoriness and a decrease in 
conduction velocity, both of which facilitate the perpetuation of AF. The arrhythmia usually 
occurs in patients with structural heart disease, and enlargement of the atria is often present, 
although it is difficult to determine whether it is the cause or the consequence of AF (14, 15). 
The prevalence of AF increases markedly with age. A review of histopathological studies 
(34) pointed out that histological alterations in the course of the normal ageing process may 
lead in turn to alterations in atrial conduction properties and thus promote the development 
of atrial arrhythmias. Atrial fibrosis facilitates AF by reducing conduction velocity and 
possibly creating areas of conduction block. The atrial activation pattern during AF is 
complex and can be difficult to interpret (35-37). Animal studies have further investigated 
these mechanisms and may improve our understanding of these complex activation patterns 
(6, 38, 39). 
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In the course of the past few years genetic defects, which mainly affect ionic currents, have 
been identified as causes of AF (40-45). Elucidation of the molecular mechanisms that cause 
familial AF might also improve our understanding of the more common acquired forms of 
the disease. Lone AF may be caused by mutations in different genes controlling cardiac 
excitability (42-45). A common feature of such genetic changes in ion channels is that they 
result in a shortening of the atrial refractory period and thus create a substrate for AF 
development. Somatic (missense) mutations in the connexin 40 encoding gene are also 
described as a non-familiar genetic disorder that leads to an increased propensity for AF (46-
47). 
The role of the autonomic nervous system in atrial fibrillation have been thoroughly studied 
(48-51) and results indicate that the occurrence of paroxysmal AF is highly dependent on 
variations in autonomic tone (52-55). There is evidence for the presence of increased atrial 
sympathetic innervation in humans with persistent AF, further suggesting that autonomic 
remodelling is a part of the atrial substrate for the maintenance of AF (56). There appears to 
be a primary increase in sympathetic tone, with a shift towards vagal predominance, before 
the onset of AF. In AF ablation, vagal denervation has been shown to potentially increase the 
success rate (50, 56) and high-density mapping and ablation of ganglionated plexi has also 
been proposed as an alternate approach for curing AF (57). 
Inflammation may also be a contributing factor in AF. Augmented levels of inflammation 
biomarkers have been reported in AF patients (58-59), and the positive effect of anti-
inflammatory agents on the prevention and modulation of AF supports this hypothesis. The 
notion that inflammation is a pathophysiological determinant in postoperative AF is also 
supported by studies (60) and further strengthens the concept of inflammation as an 
important factor in AF. 
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Electro-anatomical remodelling of the atrial tissue leads to changes in atrial conduction 
velocities, shortening and dispersions of refractory periods and atrial dilatation (61). The 
increase in atrial size correlates with the degree of atrial fibrosis (62) and may be used as a 
measure of the atrial remodelling process.  An arrhythmogenic substrate appears to be 
necessary for the perpetuation of long-lasting AF episodes, and atrial remodelling facilitates 
the self-perpetuation of AF (63, 64).   
5.3 Catheter ablation 
5.3.1 Principles of radiofrequency ablation (RFA) 
RFA induces local thermal necrosis in the heart (65). Ablation is performed in a temperature-
controlled mode and the energy output and the temperatures reached are the main 
determinants of the ablation effect. Stable catheter-tissue contact is crucial for a predictable 
ablation effect and a stronger contact force might create deeper ablation lesions (66, 67). 
Irrigation of the RFA catheter tip has also been shown to be capable of enlarging the size and 
improving the transmurality of an ablation lesion (68). The ablation lesions may be extended 
for up to 180 seconds in a single energy delivery (69, 70), although most centres use 60 
seconds as a standard application. 
5.3.2 Approaches to AF ablation 
The two main strategies for AF ablation are trigger-based and substrate-based ablation. 
Trigger-based ablation of the PVs is regarded as the cornerstone of AF ablation and the most 
frequently used methods include pulmonary vein (PV) isolation (8), PV antrum isolation (71) 
and circumferential ablation around the PVs (18, 56, 72). Adding mitral isthmus line, left 
atrial roofline ablation or both procedures is associated with an improved clinical outcome in 
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persistent and long-standing persistent AF (73, 74). Right atrial ablation may also improve 
efficacy in some patients (75).  
In substrate-based ablation, areas assumed to be responsible for the perpetuation of AF are 
localized and ablated. These areas may be identified either by mapping the atria during sinus 
rhythm (76) or by searching for complex fractionated atrial electrograms (CFAE) during AF 
(77-80). A combination of the two strategies has also been proposed (81-84). Recent clinical 
data also suggest a potential role for ganglionated plexi ablation (57). Sites of positive vagal 
response to high-frequency stimulation are ablated and energy is applied until the response is 
eliminated. 
5.3.3 Endpoints of ablation 
The goal of AF ablation is the elimination of triggers and modification of substrate using the 
least amount of ablation energy necessary. As described above, various ablation strategies, 
either solely or in combination, have been adopted. Procedural endpoints include electrical 
PV isolation with confirmed absence or dissociation of PV potentials recorded from a 
circular mapping catheter (8, 85, 86), reduction of local amplitude inside the encircled area 
(72), termination of AF during ablation (87) and non-inducibility of AF after ablation (88).  
5.4 Patient management 
5.4.1 Follow-up after AF ablation 
Reported follow-up times after AF ablation differ, but for the last few years at least 12 
months has been established as the standard protocol. There is still a need for longer-term 
(>24 months) follow-up of results after ablation. The main outcome reported after AF 
ablation procedures is AF burden, both symptomatic and asymptomatic. The ultimate success 
criterion is freedom from all atrial arrhythmias. It has been well documented that an absence 
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of symptoms does not represent the true success rate (89, 90), and more than 30% of AF 
patients have been reported to be asymptomatic (91). Perception of AF episodes might also 
change after ablation (92) because of altered heart rate or autonomic influence by ablation-
induced denervation of the heart. The accuracy of estimating the arrhythmia burden after AF 
ablation therefore depends upon the duration of the ECG recording (92-95). The best 
estimate of post-ablation arrhythmia burden and success rate demands a continuous rhythm 
recording (95-96) but five to seven days of Holter monitoring have been shown to enhance 
the sensitivity of AF detection (93-97). Transtelephonic ECG recordings have also been used 
in follow-up after AF ablation (94), but the true correlation of these to AF burden is difficult 
to determine and night episodes of AF, for example will not be recorded. About 30-50% of 
patients with recurrence of AF during the first three months after an ablation have no further 
arrhythmias (98) and therefore the first one to three months after the procedure are often 
reported as a blanking period.  
Echocardiographic examination may reveal improvements in left ventricular function in 
patients with heart failure after ablation (99). Reverse remodelling with a reduction in the 
size of the LA has also been reported (100), and different techniques, including 
echocardiography, computed tomography (CT) and magnetic resonance imaging can be used 
for LA measurements. Recently, magnetic resonance imaging has also been used to show 
atrial debulking and tissue changes after AF ablation (101). 
5.4.2 Efficacy and complications of AF ablation 
It is difficult to compare the real efficacy of AF ablation procedures because of the many 
different ablation approaches employed, different definitions of success and not least, 
different methods of follow-up. Although reported success rates have ranged from about 
40% to as high as 95%, both review articles and the worldwide surveys report that the mean 
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success rate is about 75% (101-105). Results are better for paroxysmal than persistent and 
long-standing persistent AF, and the success rates achieved would seem to have increased 
during the past few years. AF ablation is now regarded as being effective in restoring sinus 
rhythm for both paroxysmal and persistent AF, and it improves the quality of life of 
symptomatic patients. In the latest European guidelines, ablation of symptomatic drug-
refractory paroxysmal AF is categorised as a class IIa recommendation, with level of 
evidence A (15). 
Major complications occur in about 4.5% of patients (17, 103,104), typically with lower rates 
at leading centres. Reported complications consist mostly of stroke/transient ischaemic 
attack, cardiac tamponade or vascular complications such as femoral pseudoaneurism or 
arterio-venous fistula. PV stenosis used to be reported in about 1% of cases but has become 
rarer since most operators now target ablation at some distance from the ostia. Atrio-
oesophageal fistula is a serious and often fatal complication, but is very rare (104). The 
survival of patients undergoing catheter ablation for AF is similar to that of patients treated 
with anti-arrhythmic drugs, and there are no differences between these groups in rates of 
stroke or transient ischaemic attack (106). Only one non-randomised study has reported 
lower mortality and morbidity in patients treated with AF ablation than in patients on anti-
arrhythmic drugs (107), but these data need to be reproduced in larger, preferably 
randomised studies, with a longer follow-up time. 
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6 Aims of the study 
The aim of these studies was to elucidate aspects of atrial fibrillation mechanisms, mapping 
and ablation methods, and clinical results. Our specific objectives were: 
1. To investigate the different characteristics and distribution of complex fractionated 
atrial electrograms in patients with both paroxysmal and persistent AF. 
2. To elucidate the atrio-pulmonary vein conduction delay observed during pulmonary 
vein isolation. 
3. To compare the impacts of standard irrigated catheters with both irrigated and non-
irrigated magnetic guided catheters, by measuring marker levels of myocardial injury 
in atrial fibrillation ablation.   
4. To determine the relationship between arrhythmia burden, left atrial volume and 
natriuretic peptide hormone level at baseline and after long-term follow-up of atrial 
fibrillation ablation. 
5. To describe the time course and incidence of the recurrence of late atrial arrhythmia 
after pulmonary vein isolation in paroxysmal and persistent atrial fibrillation.  
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7 Methods 
7.1 Study population 
All the patients in these studies had either symptomatic paroxysmal, persistent or long-
standing persistent AF and had failed at least one anti-arrhythmic drug (2 drugs in study 2 
and 5). The patients were recruited from all parts of Norway and were referred to Haukeland 
University Hospital for AF ablation from their local hospitals or cardiologists. Studies 2 and 
5 included consecutive patients from the early years (2001-2005) of AF ablation in our 
hospital; the other studies included non-consecutive patients. Patients with both lone 
fibrillation and underlying cardiovascular disorders (including hypertension, coronary artery 
disease, valvular disease and cardiomyopathies) were included in these studies. Details of 
patient characteristics are presented in each paper. In most of the patients, antiarrhythmic 
drugs were not discontinued before the procedure, and most patients kept taking their 
antiarrhythmic drugs during a blanking period (i.e. 1-3 months after ablation). All patients 
were anticoagulated for 6 weeks prior to the procedure. Oral anticoagulation was 
discontinued in most patients two days before RFA in order to reach an international 
normalised ratio <2.3. All patients provided informed consent. The study was performed in 
accordance with the Declaration of Helsinki, and was approved by the local ethics committee 
(Regional Ethics Committee of Western Norway). 
7.2 Electrophysiological study and radiofrequency ablation 
7.2.1 Electrophysiological study 
Patients underwent electrophysiological study and RFA in a fasting, sedated state. Vascular 
access was obtained under local anesthaesia through the right and left femoral veins. In all 
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patients, a 7F 20-pole steerable mapping catheter (Livewire, St. Jude Medical Inc, St. Paul,
MN) was positioned in the coronary sinus, looped around the tricuspid annulus. After 
transseptal puncture or left-sided access through a patent oval foramen, a 10-pole circular 
mapping catheter (Lasso™, Biosense Webster, Diamond Bar, CA, USA or Optima™, St. 
Jude Medical Inc), was introduced into the LA through an 8F or 8.5F transseptal introducer. 
All patients were heparinized after transseptal puncture in order to maintain an activated 
clotting time of between 200 and 300 seconds.  
Selective angiography of all PVs was performed before and after ablation. A focus was 
defined on the basis of documented single or multiple ectopic events, with or without 
initiation of AF, and could be observed spontaneously or during provocative manoeuvres 
(isoproterenol infusion or programmed atrial pacing).  
Most patients had four PVs, but a single PV ostium on the left side (left common PV) was 
present in several patients, as was a third PV on the right side (right middle PV), which was 
isolated separately. We employed circular mapping catheters with diameters of 15, 20 or 25 
mm, based on the PV angiography. PV potentials were defined as in a previous study (108) 
and recorded in bipolar mode (Lab System Pro, Bard Electrophysiology, Lowell, MA, USA).  
7.2.2 Ablation set-up 
A 3.5 mm tip irrigated ablation catheter was used for mapping and ablation in the LA and for 
additional lines or focal ablation (a regular 4-mm tip catheter was used for the early cases 
and for one subgroup in study 3). Catheter types are specified in each study. We used a 
Stockert-Cordis radiofrequency generator (Freiburg, Germany) and energy was applied in 
temperature-controlled mode. The application time of RFA was 40-60 seconds at each site 
and energy was delivered with a cut-off temperature of 50˚ C (irrigated catheters). The 
maximum output and irrigation rates were 30-35W/15-20mL/min for PV isolation, 
23
25W/15mL/min in the coronary sinus and 30-40W/20mL/min for linear or CFAE ablation 
(maximum 35W in LA, 40W in right atrium). 
7.2.3 Ablation approach 
In the course of this study, techniques to achieve PV isolation evolved, and details of PV 
isolation are described in each paper.  In the early patients (studies 2 and 5) ablation was 
systematically performed at the earliest exit point of atrio-PV conduction, until the 
disappearance of the PV potentials. Energy was delivered at the PV ostia, without any 
attempt to obtain a wider PV circumferential ablation. In the later patients, an 
electrophysiological approach was still used, but the lesions were created at the antra of the 
PVs and circular lesions were ablated around each PV (Figure 1). If circles around the 
superior and inferior ipsi-lateral veins did not overlap, additional ablation to connect these 
lesion-sets was performed.
Additional left-sided ablation was performed in a relatively large number of patients as 
described in the individual papers. Ablation approaches included mitral isthmus line (from 
the mitral annulus to the left inferior PV), roofline (connecting the two superior PVs), two 
lines connecting the two contra-lateral superior and inferior veins, ablation on CFAEs or a 
combination. Patients with clinically documented common atrial flutter received an 
additional right-sided ablation at the cavo-tricuspid isthmus area and bi-directional isthmus 
block was confirmed.  
7.2.4 Specific mapping and ablation protocols 
In study 1, CFAE mapping during AF (Complex fractionated electrogram (CFE) mapping 
tool, St Jude Medical, St Paul, MN, USA) was performed in all patients. Three-dimensional 
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Figure 1. Left atrium, three-dimensional reconstruction, posterior-anterior view. Ablation 
lesions (white dots) are created circumferential at the antra of each pulmonary vein (PV). A 
ten bi-pole catheter are placed in the coronary sinus (CS). LSPV - left superior PV, LIPV – 
left inferior PV, RSPV right superior PV, RIPV right inferior PV.  
__________________________________________________________________________ 
reconstructions were made and global CFAE maps were generated in the left and right atria 
and the coronary sinus (Figure 2). Electrograms were sampled for eight seconds at all sites. 




Figure 2. CFAE map of left atrium (LA), right atrium (RA) and the coronary sinus (CS). Left 
panel: posterior-anterior view, right panel: left-anterior-oblique view. Areas with the shortest 
CFE mean in white, the longest CFE mean in purple. TV - Tricuspid valve, MV - Mitral valve. 
__________________________________________________________________________ 
a band-pass filter of 32 to 100 Hz. An additional noise filter was switched on if necessary. At 
each site the automated NavX algorithm calculated the “CFE mean”, which is the average 
time interval (in ms) between consecutive deflections during each sampling period. A stable 
catheter position and good tissue contact were confirmed during CFAE mapping. The CFAE 
was defined as a fractionated electrogram that comprised more than two deflections of a 
prolonged activation complex over an eight-second recording period, with either perturbation 
of the baseline (“continuous CFAE”) or a relatively clear baseline between electrograms with 
a very short cycle length  120 ms (“fragmented CFAE”). Electrograms representing a 
combination of these two characteristics were defined as “mixed CFAEs” . 
In study 2, the atrio-PV conduction delay was measured as the shortest interval from local 
atrial electrogram to the PV potential on all bipolar electrodes, and was monitored in each PV 
before and during ablation. Conduction delay was defined as the maximum atrio-PV 
26 
time interval >20 ms before PV potential disappearance during PV isolation. Figure 3 shows 
examples of PV potential disappearance and conduction delay during PV isolation. The 
patients who underwent a repeat PVI were studied separately.  
 
Figure 3. Pulmonary vein (PV) potentials recorded from a circular 10-pole catheter (Lasso 1-
10). Panel A shows sharp potentials (encircled) shortly after the atrial signals. In panel B, 
recorded during isolation of the PV, the vein potentials are delayed compared to the atrial 
signals. Panel C shows the disappearance of PV potential during ablation. panel D, recorded 
after ablation, shows complete PV isolation. ABL D and P – Recordings from the distal and 
proximal pole of the ablation catheter, respectively. 
__________________________________________________________________________ 
In study 3, patients underwent either a conventional ablation procedure, as described above, 
or a magnetic guided procedure with or without an irrigated catheter. In the patients who 
27
underwent magnetic guided ablation, the RFA catheter was introduced into the LA through a 
second transseptal guiding introducer, and LA mapping was performed by Carto™ RMT 
(Biosense Webster). The three-dimensional mapping system was used in conjunction with 
the Niobe® II system (Stereotaxis, St. Louis, MO, USA). The RFA lesion sets consisted of a 
continuous circumferential line around the two ipsilateral PVs, with additional ablation 
between the two PVs. Energy was applied only when good electrode-tissue contact was 
indicated by the system monitor. In the irrigated catheter group, a Navistar® RMT
ThermoCool® (Biosense Webster) ablation catheter was employed. Application time, output 
and temperature cut-offs and irrigation rate were the same as for conventional irrigated 
catheters. In the magnetic non-irrigated catheter group a Navistar Celsius RMT™ (Biosense 
Webster) ablation catheter was used. For some patients in this group the circular mapping 
catheter was not employed and PV isolation was confirmed by RFA catheter only (109). 
Energy was applied with a cut-off temperature of 55˚ C and a maximum output of 40W, and 
application time was 20 seconds at each site. Charring of the catheter tip raises its impedance 
and, if this was recognized, the catheter was extracted and the tip checked during the 
procedure.  
In study 4, a three-dimensional mapping system (Ensite NavX™ (St. Jude Medical Inc.) or 
Carto™XP (Biosense Webster)) was employed in all patients to guide mapping and ablation. 
Patients underwent ablation additional to PV isolation, depending on the type and duration 
of AF in each patient. 
7.3 Biomarkers                                                                                                                  
Three different biomarkers, all of which are in standard clinical use, were employed in this 
work. In studies 3 and 4, venous blood samples from an antecubital vein were obtained from 
all patients before the procedure commenced. Post-procedure samples in study 3 were 
collected 24 hours after the start of the procedure. In study 4, blood samples were drawn at 
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the long-term follow-up visit. Troponin T (TnT), Creatin Kinase’s cardiac isoform MB 
(CKMB) and N-terminal-Pro-Brain Natriuretic Peptide (NT-pro-BNP) were determined 
using an electrochemiluminescence immunoassay on a Modular E system (Roche 
Diagnostics, Mannheim, Germany). The analytical detection limits were 0.01g/L (TnT), 
0.1g/L (CKMB) and 1 pmol/L (NT-pro-BNP), respectively. The TnT cut-off value for 
diagnosis of myocardial infarction according to ACC/AHA guidelines is 0.03g/L (110).  
7.4 Imaging 
In study 4, all patients underwent cardiac computed tomography (CT) imaging on the day 
before the ablation procedure and at the final follow-up visit. Imaging was performed using 
a 64-slide scanner (Aquillion 64, Toshiba, Japan) either with or, in patients with AF during 
imaging, without ECG-gated techniques. Data were acquired during one breath-holding, 
after a bolus injection of contrast (Iomeron 400mg I/mL).  For ECG-gated images, we used 
0.5 mm and for non-gated images 1.0 mm slide thicknesses. 
LA three-dimensional reconstructions and volume computations were performed using the 
Ensite NavX™ Verismo system (St. Jude Medical Inc.). An automated algorithm calculates 
the LA volume on the basis of the three-dimensional coordinates. Before chamber volume 
was calculated, the pulmonary veins were excluded at the ostia. The LA auricle could not be 
reconstructed in all the patients, and was therefore also excluded (111). 
7.5 Follow-up 
7.5.1 Post-procedural patient management 
All patients were monitored for at least 24 hours after the procedure, and were discharged 
under oral anticoagulation. For most patients, antiarrhythmic drugs were continued for at 
least three months. Antiarrhythmic drug therapy was discontinued after successful 
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elimination of AF, and oral anticoagulation was also discontinued unless other risk factors 
were present. 
7.5.2 Clinical outcome and definitions 
In studies 3, 4 and 5, we collected data on clinical outcome. The patients were followed on 
an ambulatory basis, either in our out-patient clinic or by their own local hospitals and 
referring cardiologists. All patients underwent clinical examination and at least one Holter 
registration at three and six months after the procedure. Additional clinical examination, 
including ECG recordings, was performed if indicated by symptoms. Recurrence was strictly 
defined as 1 episode of AF after a blanking period of three months in study 3 and one 
month in study 4 and 5. In study 3, patients were followed for one year after the relevant 
ablation procedure and patients who underwent a repeat procedure during the follow-up 
period were regarded as failures. Ablation success definitions in studies 4 and 5 were based 
on the result at the end of follow-up, and patients may have undergone additional ablation 
procedures.  
7.5.3 Additional follow-up 
In study 4, all patients were examined at our clinic at the end of follow-up with a further 
seven days of cardiac rhythm monitoring using a specially developed event recorder for AF 
detection (AF Alarm, Medtronic, MN). Self-reported AF burden was graded according to a 
modified arrhythmia frequency and severity scale (112), with 1-10 points for each frequency 
and duration of AF episodes (range 2-20). AF burden was reported in all patients at baseline 
and in patients with recurrence also at follow-up. CT imaging and blood sampling were also 
performed at the end of follow-up.  
In study 5, all the patients completed a quality-of-life questionnaire at the end of the study, 
including symptoms, medications, satisfaction, and a 0–10 self-evaluation score on 
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arrhythmia burden. The clinical condition before the procedure was scored as 0 and 10 
represented complete freedom from symptoms of arrhythmia. We defined late recurrence as 
any relapse of AF between 6 and 12 months, and very late recurrence >12 months after the 
procedure.  
7.6 Statistics 
Discrete variables are reported as counts or percentages and continuous variables as mean ± 
standard deviation, or median and range for non-normal distributed data. Continuous 
variables were assessed for characteristics of distribution by the Kolmogorov-Smirnov test. 
Comparisons were performed using Student’s t-test or one-way analysis of variance 
(ANOVA) for parametric data and the Mann-Whitney U-test for non-parametric data. 
Discrete variables were compared by the 2 test or Fisher’s exact test. In study 2, trend lines 
were obtained by the method of least squares, using Microsoft Excel software (Microsoft 
Corp., Redmond, WA, USA). Correlations were calculated by means of linear regression 
analysis and Spearman’s rank correlation tests. In study 3, Levene’s test was employed to 
test the variances between groups. A receiver operator characteristic curve and best cut-off 
were calculated and plotted in study 4 using R version 2.12.0 (The R Foundation for 
Statistical Computing, Vienna, Austria). SPSS software package versions 13.0-17.0 (SPPS 
Inc., IL, USA) were used for all other statistical analyses. Values of p < 0.05 were 
considered to be statistically significant. 
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8 Results 
8.1 Paper I - Complex fractionated atrial electrograms 
In this study we investigated the different characteristics and distribution of complex 
fractionated atrial electrograms in both atria in patients with paroxysmal and persistent AF. 
Twenty AF patients (10 persistent) scheduled for ablation were included in this 
observational study.  
The NavX™ system was used to map both the left and right atria and the coronary sinus in 
all patients. An automated algorithm calculated the average time interval between 
consecutive deflections (CFE-mean). All recordings were visually inspected off-line and 
interpreted as either continuous, fragmented, mixed CFAE or non-CFAE, and their locations 
were determined. Electrograms with intermittent CFAE characteristics during the eight 
seconds recording interval were regarded as non-CFAEs.  
Persistent AF patients had more CFAEs than those with paroxysmal AF (52% vs. 44% of 
total registrations, p<0.05), and CFAEs were more widespread in both atria in persistent AF. 
There were also more continuous CFAEs (70% vs. 59% of total CFAEs, p<0.05), and fewer 
mixed and intermittent CFAEs (22% vs. 30% and 16% vs. 21% of total CFAEs, 
respectively, p<0.05) in persistent AF, indicating higher temporal signal stability. 
Fragmented CFAEs had more high-voltage signals than other groups. Employing the 
automated algorithm for CFAE mapping, a CFE-mean cut-off value of 80ms provides 
sensitivities and specificities of 87.4% and 81.2% respectively.  CFAEs seemed to be most 
common in preferential areas and displayed different patterns in the two atria. 
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8.2 Paper II - Pulmonary vein potentials  
We investigated the delay in atrio-pulmonary vein conduction during segmental PV isolation 
in various PVs in 385 AF patients (mean age: 54 ± 11 years; 74 women). PV potentials were 
registered using a circular ten-pole catheter placed at the PV ostia. The time delay from local 
atrial potential to PV potential was measured in each vein. Conduction delay was defined as 
the longest interval >20 ms before elimination of PV potentials observed during PV 
isolation.  
In patients who underwent their first PV isolation procedure, conduction delay was more 
frequently observed in the left common and right and left superior PVs (84.2%, 67.9%, and 
66.2%, respectively) and less frequently in the left and right inferior and right middle PVs 
(54.3%, 40.0%, and 30.8%, respectively). Veins with conduction delay required more 
ablation applications (12.4 vs 9.9) and a larger fraction of ablated segment (72.3% vs 
63.7%). Conduction delay was observed in 75.2% (109/145) of the PVs in which focal 
activity was detected. Older patients had a higher incidence of PVs with conduction delay 
than younger patients. No gender differences were identified. The observations of 
conduction delay in preferential PVs were not valid in patients undergoing repeat 
procedures.  
8.3 Paper III - Catheter impact on myocardial injury 
We measured myocardial markers in 114 AF patients in order to compare the effects of 
irrigated and non-irrigated remote magnetic navigated catheters with a manual irrigated 
catheter in AF ablation. The patients underwent AF ablation using either a conventional 
manual irrigated catheter (CIR, n=65) or a magnetic navigated system utilizing either an 
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irrigated (RMI, n=23) or non-irrigated catheter (RMN, n=26). Levels of TnT and CKMB 
were measured before and after ablation.  
The procedure and total ablation times were longer when the remote magnetic system was 
used. All groups displayed pronounced increases in markers of myocardial injury after 
ablation, demonstrating a significant correlation between total ablation time and post-
ablation levels of TnT and CKMB (CIR: r=0.61 and 0.53, p<0.001; RMI: r=0.74 and 0.73, 
p<0.001; and RMN: r=0.51 and 0.59, p<0.01). Time-corrected release of TnT was 
significantly higher in the CIR group than in the other groups, and remote magnetic catheters 
may create more discrete and predictable ablation lesions as measured by myocardial 
enzymes. 59.6% of the patients were free of AF at follow-up (12.2±5.4 months) and there 
were no differences in success rate between the three groups.  
8.4 Paper IV Atrial reverse remodelling  
We investigated the relationship between arrhythmia burden, LA volume and NT-pro-BNP 
at baseline and after long-term follow-up of AF ablation. We studied 38 patients (23 
paroxysmal, six women, mean age 56±11) who had been scheduled for AF ablation.  
After a mean period of 22±5 months, 28/38 patients (11/15 persistent) were free of AF 
recurrence. At baseline there were no differences in mean LA volume (125 vs. 130 cm3, 
p=0.7) or median NT-pro-BNP (33.5 vs. 29.5 pmol/L, p=0.9) between patients whose 
ablation had or had not been successful. At long-term follow-up there was a marked 
decrease in LA volume (105 vs. 134 cm3, p<0.05) and level of NT-pro-BNP (7 vs. 17.5 
pmol/L, p<0.05) in the successful ablation patients. In patients with AF recurrence, no 
statistically significant differences between baseline and follow-up measurements were 
identified. NT-pro-BNP correlated with LA volume both at baseline (r=0.71, p<0.001) and at 
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follow-up (r=0.57, p<0.001). Arrhythmia burden correlated with both NT-pro-BNP (r=0.47, 
p<0.01) and LA volume (r=0.52, p<0.01). A decrease up of > 25% of the baseline value of 
NT-pro-BNP at follow-up had a specificity of 0.89 and a sensitivity of 0.6 (receiver operator 
characteristics, accuracy 0.82) for ablation success. 
8.5 Paper V Late recurrence of AF
In this study we examined the rates and time course of AF recurrence after PV isolation at 
very long-term follow-up. We included 278 consecutive patients with drug-refractory AF 
(50 women, mean age 53±11 years). PV isolation was based on the disappearance of PV 
potentials recorded from a circumferential catheter after segmental ostium ablation. Cavo-
tricuspid isthmus lines and additional left atrial lines were performed in 124 and 28 patients 
respectively. Patients were monitored for 26±11 months (range 12–56). 
A relatively high AF recurrence rate was observed after segmental PV isolation. A total of 
120 (34 women) patients (43%) suffered a recurrence of AF, and the majority of recurrences 
occurred within six months of the first procedure. Only 14 patients (12%) experienced the 
first recurrence more than six months after the procedure. There were no differences in 
incidence or time of occurrence of late recurrences between patients with paroxysmal or 
persistent AF. A significantly higher recurrence rate was observed in patients with persistent 
AF.  
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9 General discussion 
9.1 Pathophysiology 
9.1.1 Anatomical considerations 
AF leads to remodelling of the atria, and measurements of LA size may provide important 
information. Previous studies have demonstrated that a larger LA predicts worse outcome 
after AF ablation (113). There is also evidence that LA size is a predictor of the 
cardiovascular outcome in a population (114). After successful restoration of sinus rhythm 
atrial volume may decrease due to a reverse remodelling process. In study 4, we measured 
LA volumes before and long-term after AF ablation. Our results did not identify pre-ablation 
LA volume as a predictor of ablation success, but we demonstrated a significant reduction in 
LA volume only in patients whose ablation procedure had been successful. 
There are differences in PV configuration and size both between patients and among the 
different veins in each patient. PV potential conduction delay in the different PVs was 
investigated in study 2. We found that the left common PV had the highest proportion of, 
and the longest mean, conduction delay, followed by the right superior, left superior, left 
inferior, right inferior and right middle PV. The diameter of a left common trunk is always 
large, and the superior PVs are usually larger than the inferior ones (115). This suggests that 
the incidence and duration of conduction delay are related to anatomical factors, in particular 
to the PV diameter.  
In study 1, we investigated the anatomical distribution of CFAE in both atria. Other studies 
have demonstrated a higher density of CFAE around the PVs in paroxysmal than in 
persistent AF patients (116-117). In our study, the average calculated CFE mean of the PVs 
was significantly shorter in paroxysmal than in persistent AF, although manual signal 
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interpretation did not reveal this difference. We defined the borders between the 
PVs/auricles and the atria as being located at the anatomical ostia. CFAEs located at the 
antra of the PVs and auricles were therefore counted as part of the LA, which may explain 
the differences in the observations. 
Consistent with previous studies, there were more CFAEs in the LA and CS (118-119). 
Previous studies have identified the atrial septum, LA roof, posterior LA, mitral annulus, 
base of the left auricle and the PVs as the most likely sites for CFAEs (77-79). Our study 
also revealed significantly more CFAEs in the anterior region of LA. Moreover, more 
CFAEs in the LA roof and more widely spread CFAEs in the right atrium were seen in 
persistent AF. 
9.1.2 Triggers of atrial fibrillation 
PVs are the most important structures for the initiation of AF (8). More recent evidence from 
a simulation study suggests that a mechanism of dynamically induced repolarisation 
dispersion underlies the induction of AF by atrial ectopic foci (120). The likelihood of re-
entry induction varied according to ectopic focus location and timing, with the largest 
vulnerable window corresponding to the PV region.  
In study 2 we investigated PV potential conduction delay in veins with focal trigger activity. 
Larger PVs may be associated with larger muscle fascicles connecting the PVs to the atrium 
than small PVs. A previous study concluded that patients with focal AF had larger PVs than 
controls (121). In our study PVs with focal activity displayed more conduction delay than 
PVs without such activity. PVs associated with conduction delay needed more extensive 
ablation. One possible explanation is that these veins may have larger myocardial fascicles, 
which are responsible for the focal activity. This may facilitate conduction between foci 
inside the PVs and the atrial tissue, leading to the onset of atrial fibrillation. A higher 
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incidence of conduction delays in older than in younger patients was demonstrated. One 
reason for this may be that older patients have developed more fibrotic tissue around the 
PVs, which could disturb atrio-PV conduction or create areas of slower conduction. It has 
been shown by others that PV and LA diameters increase with age (122), and in our study, 
larger veins also had a higher incidence of conduction delay. 
Several studies have identified recovered PV-LA conduction as an important factor also for 
recurrent AF after PV isolation (123-125). In study 5, we performed repeated catheter 
ablation in 54 patients, all of whom showed recovered PV conduction. However, only 
limited data regarding the extent of PV reconnection in patients after successful ablation are 
available , and the clinical utility of this finding needs further investigation. 
9.1.3 Substrate for the maintenance of atrial fibrillation 
Although the mechanisms involved are still not fully understood, there is evidence to 
connect CFAE to areas with a known pathophysiological substrate for the perpetuation of 
AF. Increased fibrosis has been demonstrated in CFAE sites compared with non-CFAE sites 
(126). In study 1, we found more CFAEs in patients with persistent AF than in paroxysmal 
AF patients. Persistent AF patients also displayed a lower proportion of high-amplitude 
signals. Electrograms in CFAE areas are of lower voltage than those in non-CFAE areas 
(127), suggesting that CFAE may be related to atrial remodelling and the extent of fibrous 
tissue. An association between CFAEs and ganglionated plexi has also been shown in an 
animal model, which suggests that mechanisms of the autonomic nervous system may also 
play a role in formation of CFAEs (128, 129). 
Konings et al. (35) classified the atrial electrograms recorded during AF into four different 
categories; single deflections, short doubles, long doubles and fragmented signals, and 
demonstrated that these signals indicated different conduction patterns. In study 1, we 
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classified two main types of fractionated atrial electrograms - fragmented and continuous 
CFAEs. The fragmented CFAEs might correspond to single deflections as described by 
Konings et al, indicating local conduction delay, and may be related to atrial microfibrosis. 
The continuous CFAEs, with an incessant perturbation of baseline, may account for the 
areas of slow conduction or pivot points of activation. In our study, patients with persistent 
AF displayed more continuous CFAEs than those with paroxysmal AF, a finding consistent 
with a previous study (130).  
Our study also revealed significantly more widely spread CFAE in the right atrium in 
persistent AF patients than in patients with paroxysmal AF, which suggests that AF may be a 
two-chamber disease in persistent AF patients. One study showed that sinus rhythm was 
restored by right atrial ablation in about 15% of patients with persistent AF (131). However, 
another study suggested that right atrial CFAEs were only “bystanders” of no clinical 
significance (78). The significance of right-sided CFAEs and the role of the right atrium for 
perpetuation of AF needs further investigation. In paroxysmal AF lower temporal signal 
stability, as demonstrated with more mixed and intermittent CFAEs, is suggestive of a lesser 
degree of atrial remodelling and thus less AF substrate. This has also been demonstrated by 
others (132). 
9.2 Catheter ablation 
9.2.1 Pulmonary vein isolation 
In the course of the past decade, AF ablation has evolved from being an experimental 
procedure to one of the most common ablations performed in the electrophysiology 
laboratory (8). PV isolation has formed the basis of ablation therapy in all our studies. 
Except for a few initial patients in studies 2 and 5, all PVs were isolated in all our patients. 
Electrical isolation has been confirmed with a circular mapping catheter in the PV ostium in 
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all patients, except for a subgroup in study 3. New methods of PV isolation have been 
developed in the course of this work. In the earlier patients (studies 2 and 5), a segmental 
approach, as initially described by Haïssaguerre (8), was adopted, with ablation applications 
closer to the ostium. In studies 3 and 4, energy was applied circumferentially around each 
PV antrum. In re-isolations of PVs, fewer ablation applications were needed, as we have 
shown in study 2.  
In study 3, we performed AF ablation procedures using three different catheters in a non-
randomized study. There were no statistically significant differences in outcome using the 
different ablation catheters. Nor were there any differences in marker levels in patients 
whose ablation were or were not successful. Longer procedure and ablation application 
times were shown when a circular mapping catheter was employed to confirm PV isolation 
(non-irrigated magnetic navigated group), which may indicate a more thorough ablation 
procedure. A better clinical outcome when PV isolation is confirmed has been demonstrated 
by other studies (133, 134).  
9.2.2 Different ablation approaches 
In the initial patients described in study 5, there were very high recurrence rates among 
patients with persistent and long-standing persistent AF. Other clinical studies have also 
demonstrated poor results after trigger-based ablation alone in patients with persistent AF 
(18), and extensive ablation is required to obtain stable sinus rhythm (135). Multiple 
procedures and additional ablation strategies are often required to restore stable sinus 
rhythm. Different approaches have been shown to improve the outcomes. Adding left atrial 
lines has been shown to be effective in improving clinical outcome in persistent and long-
standing persistent AF (73, 74). Right atrial ablation may also provide incremental 
improvements in some patients (75). Several studies have also shown an improved outcome 
when fractionated electrograms are targeted in addition to PV isolation (136, 137). The 
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strategy of CFAE ablation is based on the hypothesis that the areas with CFAE are essential 
for the perpetuation of AF (77). The differences in success within and between techniques 
suggest that the optimal ablation technique for the treatment of persistent and especially 
long-standing persistent AF is unclear. Nevertheless, long-standing persistent AF can also be 
effectively treated by a combination of extensive index catheter ablation and repeat 
procedures (138). In study 3, there were no differences in clinical outcome using different 
catheter types. The proportion of tailored ablation in addition to PV isolation was similar in 
all groups, which suggests that the choice of procedural strategy is more important than the 
type of catheter used to reach the ablation endpoints. 
9.2.3 Catheters and technology 
Catheters and mapping technology have evolved in the course of the past decade. Irrigated 
ablation catheters and three-dimensional mapping systems have become standard equipment. 
Other aspects of ablation technology have also been shown to be feasible, and a wide range 
of specialised catheters designed for PV isolation have been developed. A circular multi-
electrode ablation catheter, a high-density basket catheter and a cryoballoon catheter are 
available on the market, and studies using laser technology (laser balloon) have also been 
performed. These catheters are placed at the LA-PV antrum and provide clinical outcomes 
similar to those of standard point-by-point PV isolation (139-140). 
In study 3 we employed a remote magnetic navigation system and compared the ablation 
effect, as indicated by myocardial marker release, to manual irrigated catheters. 
Considerably lower time-corrected TnT level was associated with the magnetic navigated 
system, whether irrigated or non-irrigated catheters were employed. This suggests that 
myocardial injury, as indicated by enzyme release, was lower with the magnetic system than 
when the manual ablation technique was employed. One possible explanation for this is that 
lesions created by the magnetic navigated catheters may be more sharply defined, because of 
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the positional stability of the system, than those made with manual catheters. The manual 
catheters may be less stable and may slide over the endocardium, resulting in larger, but 
shallower and thus less effective, ablation lesions. This lack of stability may also create more 
undesirable myocardial damage. Magnetic navigated catheters may therefore cause less 
myocardial damage and still be effective. It has been suggested that similar mechanisms are 
involved in cryoablation, when the ablation catheter freezes to the endocardium (141-142). 
With the magnetic navigated system, catheter-tissue contact status can be monitored, but no 
guidance of catheter-tissue contact was available with manual catheter ablation. Others have 
demonstrated that a substantially stronger contact force might create deeper ablation lesions 
(66, 143).  
In the early years of AF ablation, navigation in the LA was performed using fluoroscopy and 
electrogram interpretation alone (8, 108). Later, the use of three-dimensional navigation 
systems have been adopted in most AF ablation procedures. These systems incorporate 
various tools, such as image integration and automated signal interpretation. In studies 1, 3 
and 4, we utilised navigation systems for guidance of mapping and ablation.  
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9.3 Patient management 
9.3.1 Follow-up after ablation 
Patients in this study were followed up on an out-patient basis. Anti-arrhythmic drugs were 
discontinued after three to six months if they were free of AF. Oral anti-coagulants were 
discontinued after six months if no risk factors were identified.  
In study 4, we investigated the relationship of NT-pro-BNP and LA volume to ablation 
success. In accordance with the results of previous studies (144, 145), baseline NT-pro-BNP 
values decreased significantly in patients after successful restoration of sinus rhythm. 
Patients with recurrence of AF had no significant reduction in NT-pro-BNP after ablation. 
Even though we included patients with low AF burden and baseline NT-pro-BNP within the 
normal range, the decrease of NT-pro-BNP in patients after successful ablation was 
statistically significant and correlated with the reduction in LA volume. NT-pro-BNP before 
ablation was not a valid predictor of ablation outcome, but measurement of NT-pro-BNP at 
baseline and follow-up may add value to the clinical evaluation of ablation success. In 
accordance with a previous study (146), we found that LA volume was more robust than LA 
anterioposterior diameter as a marker of successful ablation. Other studies have shown that 
the measurement of NT-pro-BNP and LA size add incremental predictive value before AF 
ablation (113, 144, 147). In our study, baseline values of NT-pro-BNP and LA size did not 
differ in patients whose ablation had or had not been successful. Augmented LA dimensions 
have been observed in patients with recurrent AF (148), but we could not reproduce this 
finding. However, some of our patients whose ablation was unsuccessful did experience a 
marked decrease in AF burden, which may have influenced the degree of LA dilatation.  
9.3.2 Efficacy and complications                                                                                            
We provided long-term follow-up data in studies 3, 4 and 5, and reported success rates 
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comparable to other published data. In studies 3 and 5, the definition of success was based 
on clinical examinations, self-reported symptoms, ECG recordings and 24-hour Holter 
monitoring. After ablation, asymptomatic AF may be present, and 24-hour Holter 
monitoring may therefore not provide a true measure of success (92). The patients in study 4 
therefore underwent an additional long-term event recording session at the end of follow-up. 
Previous studies have documented high recurrence rates in persistent AF following PV 
isolation alone (18), consistent with our findings in study 5. At the time of follow-up in this 
study, 12% of all recurrences had occurred later than six months after RFA. We found no 
differences in the time of recurrence between paroxysmal and persistent AF patients. It has 
been suggested that there may be a larger proportion of right-sided trigger mechanisms in 
patients with very late recurrences of AF (123), but the timelines and mechanisms of late AF 
recurrences have not yet been fully elucidated. 
Thromboembolisation from the LA auricle is one of the most important causes of AF-related 
stroke events and impaired function, and dilatation of the auricle has been associated with 
thrombus formation. Reverse remodelling of the LA auricle after successful AF ablation 
(149) could theoretically indicate a decrease in thromboembolic risk after ablation. We 
excluded the LA auricle from the volume calculations and therefore cannot provide data on 
this topic.  
One patient in study 5 had a major PV stenosis that required intervention. In study 4, we 
identified one patient with an asymptomatic PV narrowing, but for the other studies we 
cannot provide data, and patients were not investigated if there were no symptoms 
suggestive of PV injury. Some patients were observed for pericardial effusion after ablation 
without need for intervention, but none developed cardiac tamponade. No other procedure-
related complications, such as atrio-eosophageal fistula, transient ischaemic attack or major 
bleeding, were observed. 
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9.4 Study limitations 
All the studies were non-randomized and from the experience of a single centre, which 
limits the significance of outcome comparisons between groups. Studies 1 and 2 were 
observational studies without clinical data on ablation outcome. The numbers of patients in 
study 1, 3 and 4 were relatively small. In accordance with other studies, there were 
significantly more male than female patients. Specific gender differences were not further 
explored. Some patients underwent individually tailored ablation in addition to PV isolation, 
which also may limit the interpretation of the clinical results between groups.
9.5 Future perspectives 
Although much progress has been made in both techniques and equipment for AF ablation 
during the past few years, new methods will continue to evolve. Traditional RFA may be 
challenged by the further development of other energy sources such laser or cryoenergy, and 
new navigation and catheter-handling methods are in constant progress. There will be a need 
for randomized multi-centre studies that focus on the development and quality assurance of 
both methods and technology. A growing population of AF patients may necessitate better 
guidelines for both the selection of patients beneficial for ablation, especially long-standing 
persistent AF, and ablation approaches. More standardised patient follow-up methods would 
have enabled better comparisons of clinical data and outcomes to be made. Only limited data 
on very-long term success rates are as yet available, and there is a need for larger studies on 
stroke risk and long-term mortality and morbidity after AF ablation.
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10 Conclusions 
1. Complex fractionated atrial electrograms tend to occur in certain areas and in 
different patterns in both atria. The left atrium and coronary sinus are more 
fractionated than the right atrium. Patients with persistent atrial fibrillation tend to 
have more fractionated electrograms and more continuous fractionated electrograms, 
and they display higher temporal signal stability than patients with paroxysmal AF.  
2. The left common and superior pulmonary veins have a higher incidence of 
conduction delay during the first pulmonary vein isolation procedure than the usually 
smaller inferior veins. Conduction delay is more often observed in older patients and 
in those pulmonary veins that display focal activity. Veins with conduction delay 
required more ablation applications and a larger area of ablation around the ostia. 
3. Remote magnetic navigated catheters may create more discrete ablation lesions with 
a more predictable effect as measured by myocardial enzymes. This system may 
require longer ablation time to reach the procedural endpoints than manual 
procedures. Remote magnetic non-irrigated catheters do not appear to be inferior to 
magnetic irrigated catheters in terms of myocardial marker release and clinical 
outcome.  
4. NT-pro-BNP correlates with atrial volume and arrhythmia burden in AF patients. At 
long-term follow-up there is a marked decrease in left atrial volume and NT-pro-
BNP only in patients whose ablation has been successful. A decrease in NT-pro-BNP 
of >25% from the baseline value may be a useful marker of ablation success. 
5. Segmental pulmonary isolation has a relatively high recurrence rate, and there is an 
increase in the recurrence rate also later than 12 months after the procedure. 
Nevertheless, the vast majority of AF recurrence occurred earlier than six months 
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after RFA. No differences in the time course of late recurrence in patients with either 
paroxysmal or persistent atrial fibrillation were observed. 
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